Ligand Pharmaceuticals Incorporated

LGND · NASDAQ
Analyze with AI
9/30/2025
6/30/2025
3/31/2025
12/31/2024
Operating Activities
Net Income$117$5-$42-$31
Dep. & Amort.$7$9$9$9
Deferred Tax$9-$0-$9-$13
Stock-Based Comp.$15$0$0$8
Change in WC$11-$6-$5$12
Other Non-Cash-$146$9$22$44
Operating Cash Flow$13$16-$26$28
Investing Activities
PP&E Inv.-$0-$0-$2-$1
Net Acquisitions$0$0$0$80
Inv. Purchases-$392-$63-$59-$97
Inv. Sales/Matur.$53$51$71$45
Other Inv. Act.$4$2-$4-$66
Investing Cash Flow-$334-$11$5-$39
Financing Activities
Debt Repay.$0-$0-$0-$0
Stock Issued-$12$8$4$3
Stock Repurch.$0$0$0$0
Dividends Paid$0$0$0$0
Other Fin. Act.-$10$7-$9$17
Financing Cash Flow-$10$15-$5$20
Forex Effect$0-$0$1-$2
Net Chg. in Cash-$68$20-$24$9
Supplemental Information
Beg. Cash$68$48$72$64
End Cash$0$68$48$72
Free Cash Flow$13$16-$26$28